Biofourmis, an AI well being IT firm primarily based in Singapore, at the moment introduced it raised $100 million in a sequence C funding spherical led by SoftBank’s Imaginative and prescient Fund 2. CEO Kuldeep Singh Rajput mentioned the corporate will use the proceeds to speed up enlargement, advance therapeutics pipelines, develop care pathways, and drive integration with well being system, hospital, pharmaceutical, and analysis shoppers. Biofourmis additionally plans to commercialize new digital therapeutics options throughout cardiology, respiratory, oncology, and ache segments with a deal with Asian Pacific, Chinese language, and Japanese markets.
Linked gadgets acquire an unbelievable quantity of sufferers’ knowledge — known as biomarkers — that can be utilized to foretell quite a lot of health-related outcomes. Biofourmis asserts biomarkers might inform an goal measure of ache, for example; the corporate lately engaged Chugai Pharmaceutical to find methods to measure discomfort related to endometriosis, a dysfunction during which endometrial tissue grows exterior of the uterus. Biofourmis asserts that biomarkers allow distant affected person monitoring, liberating up clinicians to handle sufferers who urgently require in-person care.
Biofourmis describes its end-to-end Biovitals platform as a “physiology-based knowledge analytics engine” for well being care suppliers, payers, and pharmaceutical firms. Algorithms repeatedly ingest knowledge from affected person well being histories and FDA-approved wearable sensors to create biomarkers reflecting total well being, producing disease- and therapy-specific fashions for maladies like coronary heart failure, ache, and myocardial infarction.
Biofourmis says Biovitals can detect adjustments in well being “days” sooner than conventional screenings and that it ties in with digital well being document (EHR) programs, enabling the service to alert docs when an intervention is likely to be vital. Biovitals biomarkers additionally drive vitamin, health, and remedy regimens, in addition to the reminders sufferers obtain via Biofourmis’ companion smartphone app.
Biofourmis’ different highlight product — BiovitalsHF — is designed to facilitate monitoring of coronary heart failure sufferers with instruments that ship perception concerning remedy effectiveness, drug dosage variances, and hostile reactions. The corporate says a few of its clients are utilizing BiovitalsHF together with pharmacotherapy to offer in-home care, with the objective of lowering hospital readmissions and limiting emergency room visits.
It’s been an eventful 12 months for Biofourmis, to place it mildly. In July 2019, the corporate partnered with researchers at Yale and the Mayo Clinic to check endpoints for coronary heart illness utilizing Apple Watches and Biofourmis’ cell well being monitor. In October, the FDA granted the Biovitals analytics engine 510(okay) clearance as a medical machine for ambulatory physiological monitoring. A month later, Novartis tapped Biofourmis to assist develop digital therapeutic packages that observe sufferers residence after they’ve been identified with coronary heart failure. And simply this 12 months, Biofourmis launched into a program with the College of Hong Kong to help with monitoring and treating COVID-19 sufferers.
Biofourmis additionally made two acquisitions geared toward bolstering its well being know-how platform. Final November, the corporate snatched up Zurich-based wearable firm Biovotion, a startup growing a biosensor that may ostensibly measure 22 completely different very important indicators. And in April, it finalized an settlement to amass Gaido Well being from Takeda Prescribed drugs, a deal that expands Biofourmis’ portfolio within the oncology area.
Rajput says that income has elevated “considerably” via the brand new collaborations with seven pharmaceutical firms and 10 well being programs. He declined to disclose a precise valuation, however mentioned that Biofourmis is now value round $1 billion.
Along with SoftBank, Biofourmis’ newest funding spherical had participation from present buyers EDBI, MassMutual Ventures, Openspace Ventures, and Sequoia Capital. It brings the corporate’s complete raised so far to over $143 million, and it marks the adoption of Biofourmis’ new organizational construction. A division known as Biofourmis Therapeutics will deal with growing software-based therapeutics, whereas a separate entity — Biofourmis Well being — will work on digital care fashions to remotely handle sufferers transitioning to post-care.